XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash Flows from Operating Activities    
Net income $ 2,825 $ 4,307
Adjustments to reconcile net income to net cash provided by operating activities:    
Amortization 543 699
Depreciation 448 421
(Income) loss from investments in equity securities, net (450) 708
Charge for the acquisition of Imago BioSciences, Inc. 1,192 0
Deferred income taxes (277) (338)
Share-based compensation 145 120
Other (197) 143
Net changes in assets and liabilities (2,890) (1,299)
Net Cash Provided by Operating Activities 1,339 4,761
Cash Flows from Investing Activities    
Capital expenditures (1,007) (984)
Purchases of securities and other investments (562) (372)
Proceeds from sales of securities and other investments 500 1
Acquisition of Imago BioSciences, Inc., net of cash acquired (1,327) 0
Other 37 182
Net Cash Used in Investing Activities (2,359) (1,173)
Cash Flows from Financing Activities    
Payments on debt (1) (1,250)
Purchases of treasury stock (149) 0
Dividends paid to stockholders (1,853) (1,745)
Proceeds from exercise of stock options 30 12
Other (81) (103)
Net Cash Used in Financing Activities (2,054) (3,086)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 87 (55)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (2,987) 447
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets) 12,773 8,167
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March 31, 2023 and 2022, respectively, included in Other current assets) $ 9,786 $ 8,614